347 related articles for article (PubMed ID: 31353861)
1. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model.
Koene LMC; van Grondelle SE; Proietti Onori M; Wallaard I; Kooijman NHRM; van Oort A; Schreiber J; Elgersma Y
Ann Clin Transl Neurol; 2019 Jul; 6(7):1273-1291. PubMed ID: 31353861
[TBL] [Abstract][Full Text] [Related]
2. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
[TBL] [Abstract][Full Text] [Related]
3. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
4. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
6. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
Guo D; Zhang B; Han L; Rensing NR; Wong M
Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
[TBL] [Abstract][Full Text] [Related]
7. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
8. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
9. TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice.
Abs E; Goorden SM; Schreiber J; Overwater IE; Hoogeveen-Westerveld M; Bruinsma CF; Aganović E; Borgesius NZ; Nellist M; Elgersma Y
Ann Neurol; 2013 Oct; 74(4):569-79. PubMed ID: 23720219
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng LH; Xu L; Gutmann DH; Wong M
Ann Neurol; 2008 Apr; 63(4):444-53. PubMed ID: 18389497
[TBL] [Abstract][Full Text] [Related]
11. Role of mTOR inhibitors in epilepsy treatment.
Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.
Zhang B; Zou J; Rensing NR; Yang M; Wong M
Neurobiol Dis; 2015 Aug; 80():70-9. PubMed ID: 26003087
[TBL] [Abstract][Full Text] [Related]
13. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
[TBL] [Abstract][Full Text] [Related]
14. The natural history and treatment of epilepsy in a murine model of tuberous sclerosis.
Erbayat-Altay E; Zeng LH; Xu L; Gutmann DH; Wong M
Epilepsia; 2007 Aug; 48(8):1470-6. PubMed ID: 17484760
[TBL] [Abstract][Full Text] [Related]
15. Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.
Zou J; Zhang B; Gutmann DH; Wong M
Epilepsia; 2017 Dec; 58(12):2053-2063. PubMed ID: 29023667
[TBL] [Abstract][Full Text] [Related]
16. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.
Brandt C; Hillmann P; Noack A; Römermann K; Öhler LA; Rageot D; Beaufils F; Melone A; Sele AM; Wymann MP; Fabbro D; Löscher W
Neuropharmacology; 2018 Sep; 140():107-120. PubMed ID: 30081001
[TBL] [Abstract][Full Text] [Related]
17. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
Overwater IE; Rietman AB; Bindels-de Heus K; Looman CW; Rizopoulos D; Sibindi TM; Cherian PJ; Jansen FE; Moll HA; Elgersma Y; de Wit MC
Neurology; 2016 Sep; 87(10):1011-8. PubMed ID: 27511181
[TBL] [Abstract][Full Text] [Related]
20. Early developmental electroencephalography abnormalities, neonatal seizures, and induced spasms in a mouse model of tuberous sclerosis complex.
Rensing N; Johnson KJ; Foutz TJ; Friedman JL; Galindo R; Wong M
Epilepsia; 2020 May; 61(5):879-891. PubMed ID: 32274803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
